Advertisement
Product › Details
genome editing (gene editing)
Next higher product group | nucleic acid editing technology (DNA/RNA-editing technology) | |
Record changed: 2024-04-28 |
Advertisement
More documents for nucleic acid editing technology (DNA/RNA-editing technology)
- [1] ERS Genomics Ltd.. (3/26/24). "Press Release: Key Charpentier/Doudna CRISPR Patent Upheld by China National Intellectual Property Administration". Dublin....
- [2] ERS Genomics Ltd.. (3/13/24). "Press Release: Ricoh and ERS Genomics Enter into CRISPR/Cas9 License Agreement". Tokyo & Dublin....
- [3] Tome Biosciences, Inc.. (12/12/23). "Press Release: Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integration Platform". Watertown, MA....
- [4] Epic Bio (Epicrispr Biotechnologies, Inc.). (7/12/22). "Press Release: Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine with Epigenetic Engineering". South San Francisco, CA....
- [5] Integra Thepeutics S.L.. (3/29/22). "Press Release: Integra Therapeutics Closes a New Investment of €1.5 Million with the Addition of Columbus Venture Partners to Seed Round". Barcelona....
- [6] Synthego Corporation. (2/17/22). "Press Release: Synthego Raises $200 Million to Accelerate the Field of CRISPR-Based Medicines from Early-Phase Research to the Clinic. Company Appoints Avi Raval as Chief Financial Officer". Redwood City, CA....
- [7] Metagenomi Inc.. (1/25/22). "Press Release: Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform". Emeryville, CA....
- [8] Integra Thepeutics S.L.. (12/2/21). "Press Release: Integra Tx Secures €4.5 Million in Funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures". Barcelona....
- [9] Poseida Therapeutics, Inc.. (10/12/21). "Press Release: Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies". San Diego, CA....
- [10] ERS Genomics Ltd.. (6/1/21). "Press Release: Japanese Patent Office Upholds Key Charpentier/Doudna CRISPR Patent and Allows Third". Dublin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top